Dove Medical warning letter rescinded by FDA due to agency filing error.
This article was originally published in The Gray Sheet
Executive Summary
DOVE MEDICAL WARNING LETTER ISSUED DUE TO FILING ERROR has been rescinded, FDA says in a Nov. 5 letter to the company. The Oct. 29 warning letter cited the firm for not filing an initial product report or annual reports for its OsteoAnalyzer. In the rescission letter, FDA acknowledges that it mistakenly issued the letter because it could not locate files.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.